{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:35:22Z","timestamp":1772217322095,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.bbcan.2022.188825","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:24:29Z","timestamp":1666225469000},"page":"188825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel approach to reducing disparities in health outcomes by enhancing interpretation of cancer clinical trials for underrepresented patient groups"],"prefix":"10.1016","volume":"1877","author":[{"given":"Sean","family":"Khozin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger M.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2022.188825_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2105\/AJPH.2007.126847","article-title":"The importance of external validity","volume":"98","author":"Steckler","year":"2008","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.bbcan.2022.188825_bb0010","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1002\/cncr.21907","article-title":"Generalizability of cancer clinical trial results","volume":"106","author":"Elting","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2022.188825_bb0015","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1056\/NEJMms1603756","article-title":"\u201cEthics and clinical research\u201d \u2014 the 50th anniversary of Beecher\u2019s bombshell","volume":"374","author":"Jones","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188825_bb0020","author":"Yearby"},{"key":"10.1016\/j.bbcan.2022.188825_bb0025","author":"HEW: Belmont Report [Internet]"},{"key":"10.1016\/j.bbcan.2022.188825_bb0030","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.162.15.1682","article-title":"Representation of the elderly, women, and minorities in heart failure clinical trials [internet]","volume":"162","author":"Heiat","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bbcan.2022.188825_bb0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-pharmtox-010814-124614","article-title":"How good is \u201cevidence\u201d from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?","volume":"55","author":"Naci","year":"2015","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbcan.2022.188825_bb0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1749-6632.2009.05339.x","article-title":"Race, socioeconomic status and health: complexities, ongoing challenges and research opportunities","author":"Williams","year":"2010","journal-title":"An. NY Acad. Soc."},{"key":"10.1016\/j.bbcan.2022.188825_bb0045","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2022.188825_bb0050","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188825_bb0055","author":"SEER Incidence Database - SEER Data & Software [Internet]"},{"issue":"10","key":"10.1016\/j.bbcan.2022.188825_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2022.188825_bb0065","series-title":"FDA sets an example through Eli Lilly, Innovent\u2019s PD-1, rocking the boat for future contenders: analyst [internet], Fierce Pharma.","author":"Liu","year":"2022"},{"key":"10.1016\/j.bbcan.2022.188825_bb0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2022.188825_bb0075","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria \u2014 balancing patient protection and participation in oncology trials","volume":"376","author":"Beaver","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188825_bb0080","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1200\/JCO.18.01132","article-title":"Addressing financial barriers to patient participation in clinical trials: ASCO policy statement","volume":"36","author":"Winkfield","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2022.188825_bb0085","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1740774509102563","article-title":"Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality?","volume":"6","author":"Weisberg","year":"2009","journal-title":"Clin. Trials Lond. Engl."},{"key":"10.1016\/j.bbcan.2022.188825_bb0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/aje\/kwq084","article-title":"Generalizing evidence from randomized clinical trials to target populations","volume":"172","author":"Cole","year":"2010","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.bbcan.2022.188825_bb0095","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Spall","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2022.188825_bb0100","series-title":"Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again","author":"Topol","year":"2019"},{"key":"10.1016\/j.bbcan.2022.188825_bb0105","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx187","article-title":"Pazdur R: real-world data for clinical evidence generation in oncology [internet]. JNCI","volume":"109","author":"Khozin","year":"2017","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2022.188825_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41746-019-0203-0","article-title":"Digital clinical trials: creating a vision for the future","volume":"2","author":"Steinhubl","year":"2019","journal-title":"Npj Digit. Med."},{"key":"10.1016\/j.bbcan.2022.188825_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066844","article-title":"Systematic review of the empirical evidence of study publication bias and outcome reporting bias\u2014an updated review","volume":"8","author":"Dwan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2022.188825_bb0120","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jama.1992.03480030052036","article-title":"Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards","volume":"267","author":"Dickersin","year":"1992","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.bbcan.2022.188825_bb0125","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s11606-018-4425-7","article-title":"Empirical comparison of publication bias tests in meta-analysis","volume":"33","author":"Lin","year":"2018","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.bbcan.2022.188825_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/pam.21660","article-title":"External validity in policy evaluations that choose sites purposively","volume":"32","author":"Olsen","year":"2013","journal-title":"J. Policy Anal. Manage"},{"key":"10.1016\/j.bbcan.2022.188825_bb0135","series-title":"LiveScience M: race is a social construct, scientists argue [Internet], Sci. Am.","author":"Gannon","year":"2020"},{"key":"10.1016\/j.bbcan.2022.188825_bb0140","series-title":"Active Credit Portfolio Management in Practice","author":"Bohn","year":"2009"},{"key":"10.1016\/j.bbcan.2022.188825_bb0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2307\/1912352","article-title":"Sample selection bias as a specification error","volume":"47","author":"Heckman","year":"1979","journal-title":"Econometrica"},{"key":"10.1016\/j.bbcan.2022.188825_bb0150","series-title":"Annals of Economic and Social Measurement","article-title":"The common structure of statistical models of truncation, sample selection and limited dependent variables and a simple estimator for such models [internet]","volume":"Vol. 5","author":"Heckman","year":"1976"},{"key":"10.1016\/j.bbcan.2022.188825_bb0155","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1158\/1078-0432.CCR-20-3857","article-title":"Impact of broadening trial eligibility criteria for patients with advanced non\u2013small cell lung cancer: real-world analysis of select ASCO-friends recommendations","volume":"27","author":"Harvey","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188825_bb0160","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1634\/theoncologist.2018-0307","article-title":"Real-world outcomes of patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors in the year following U.S. regulatory approval","volume":"24","author":"Khozin","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bbcan.2022.188825_bb0165","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cpt.1441","article-title":"Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations","volume":"106","author":"Khozin","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2022.188825_bb0170","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","article-title":"Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer","volume":"36","author":"Griffith","year":"2019","journal-title":"Adv. Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X22001500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X22001500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:42:50Z","timestamp":1759639370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X22001500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0304419X22001500"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188825","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel approach to reducing disparities in health outcomes by enhancing interpretation of cancer clinical trials for underrepresented patient groups","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188825","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188825"}}